Page 230 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 230
Viral Hepatitis: Hepatitis B & D - Clinical (Therapy, New Compounds, Resistance) (Cont.)
P0638 GLOBAL EPIDEMIOLOGY OF HEPATITIS DELTA:
FIRST DATA FROM THE HEPATITIS DELTA
INTERNATIONAL NETWORK
Svenja Hardtke*, Zaigham Abbas, Saeed Hamid, Emanoil Ceausu,
Georgios N. Dalekos, Grazia Niro, Giampaolo Corti,
Lourdes M. Pinheiro Borzacov, Raimundo Parana, Nikolaos K. Gatselis,
Adriana Motoc, Patrick Ingiliz, Marion Muche, Anika Wranke,
Michael Wöbse, Cihan Yurdaydin, Michael P. Manns, Heiner Wedemeyer,
Germany
P0639 TELBIVUDINE VERSUS TENOFOVIR-BASED TREATMENT
OPTIMISATION STRATEGY IN HBEAG-NEGATIVE CHRONIC
HEPATITIS B PATIENTS
Zahari Krastev *, Iskren Kotzev, Mustafa K. Celen, David McNeeley,
Kamal Hamed, Bulgaria
P0640 EFFECT OF THE COMBINATION OF THE HBV CORE
INHIBITOR NVR 3-778 WITH NUCLEOSIDE ANALOGS OR
ePOSTERS OTHER HBV CORE INHIBITORS ON THE INHIBITION OF
HBV DNA REPLICATION IN HEPG2.2.15 CELLS
Angela Lam*, Christine Espiritu, Osvaldo Flores, George Hartman,
Klaus Klumpp, The United States
P0641 EXCELLENT 5-YEAR SURVIVAL IN CAUCASIAN CHRONIC
HEPATITIS B (CHB) PATIENTS WITH OR WITHOUT
CIRRHOSIS UNDER LONG-TERM ENTECAVIR (ETV)
OR TENOFOVIR (TDF) THERAPY AND THE IMPACT OF
HEPATOCELLULAR CARCINOMA (HCC)
George Papatheodoridis*, George Dalekos, Cihan Yurdaydin,
Maria Buti, Vana Sypsa, John Goulis, Jose Luis Calleja, Heng Chi,
Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis,
Onur Keskın, Savvoula Savvidou, Juan De La Revilla, Bettina E. Hansen,
Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idılman,
Massimo Colombo, Rafael Esteban, Harry L. Janssen, Pietro Lampertico,
Greece
P0642 THE EFFICACY AND SAFETY OF TELBIVUDINE OR
TENOFOVIR DISOPROXIL IN PRENGANCEY FOR
PREVENTION OF MOTHER –TO-CHILD TRANSMISSION OF
HEPATITIS B VIRUS
Hongfei Huang,Yanqiong Zhang, Quanxin Wu,Yuming Wang*, China
230 The International Liver Congress™ 2015 • ILC Programme
P0638 GLOBAL EPIDEMIOLOGY OF HEPATITIS DELTA:
FIRST DATA FROM THE HEPATITIS DELTA
INTERNATIONAL NETWORK
Svenja Hardtke*, Zaigham Abbas, Saeed Hamid, Emanoil Ceausu,
Georgios N. Dalekos, Grazia Niro, Giampaolo Corti,
Lourdes M. Pinheiro Borzacov, Raimundo Parana, Nikolaos K. Gatselis,
Adriana Motoc, Patrick Ingiliz, Marion Muche, Anika Wranke,
Michael Wöbse, Cihan Yurdaydin, Michael P. Manns, Heiner Wedemeyer,
Germany
P0639 TELBIVUDINE VERSUS TENOFOVIR-BASED TREATMENT
OPTIMISATION STRATEGY IN HBEAG-NEGATIVE CHRONIC
HEPATITIS B PATIENTS
Zahari Krastev *, Iskren Kotzev, Mustafa K. Celen, David McNeeley,
Kamal Hamed, Bulgaria
P0640 EFFECT OF THE COMBINATION OF THE HBV CORE
INHIBITOR NVR 3-778 WITH NUCLEOSIDE ANALOGS OR
ePOSTERS OTHER HBV CORE INHIBITORS ON THE INHIBITION OF
HBV DNA REPLICATION IN HEPG2.2.15 CELLS
Angela Lam*, Christine Espiritu, Osvaldo Flores, George Hartman,
Klaus Klumpp, The United States
P0641 EXCELLENT 5-YEAR SURVIVAL IN CAUCASIAN CHRONIC
HEPATITIS B (CHB) PATIENTS WITH OR WITHOUT
CIRRHOSIS UNDER LONG-TERM ENTECAVIR (ETV)
OR TENOFOVIR (TDF) THERAPY AND THE IMPACT OF
HEPATOCELLULAR CARCINOMA (HCC)
George Papatheodoridis*, George Dalekos, Cihan Yurdaydin,
Maria Buti, Vana Sypsa, John Goulis, Jose Luis Calleja, Heng Chi,
Spilios Manolakopoulos, Giampaolo Mangia, Nikolaos Gatselis,
Onur Keskın, Savvoula Savvidou, Juan De La Revilla, Bettina E. Hansen,
Ioannis Vlachogiannakos, Kostantinos Galanis, Ramazan Idılman,
Massimo Colombo, Rafael Esteban, Harry L. Janssen, Pietro Lampertico,
Greece
P0642 THE EFFICACY AND SAFETY OF TELBIVUDINE OR
TENOFOVIR DISOPROXIL IN PRENGANCEY FOR
PREVENTION OF MOTHER –TO-CHILD TRANSMISSION OF
HEPATITIS B VIRUS
Hongfei Huang,Yanqiong Zhang, Quanxin Wu,Yuming Wang*, China
230 The International Liver Congress™ 2015 • ILC Programme
